141 related articles for article (PubMed ID: 15205914)
21. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of perillyl alcohol in patients with refractory malignancies.
Murren JR; Pizzorno G; DiStasio SA; McKeon A; Peccerillo K; Gollerkari A; McMurray W; Burtness BA; Rutherford T; Li X; Ho PT; Sartorelli A
Cancer Biol Ther; 2002; 1(2):130-5. PubMed ID: 12170772
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
24. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Villalona-Calero MA; Eckhardt SG; Weiss G; Hidalgo M; Beijnen JH; van Kesteren C; Rosing H; Campbell E; Kraynak M; Lopez-Lazaro L; Guzman C; Von Hoff DD; Jimeno J; Rowinsky EK
Clin Cancer Res; 2002 Jan; 8(1):75-85. PubMed ID: 11801542
[TBL] [Abstract][Full Text] [Related]
25. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
27. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.
da Fonseca CO; Linden R; Futuro D; Gattass CR; Quirico-Santos T
Arch Immunol Ther Exp (Warsz); 2008; 56(4):267-76. PubMed ID: 18726148
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
[TBL] [Abstract][Full Text] [Related]
29. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Rowinsky EK; Humphrey R; Hammond LA; Aylesworth C; Smetzer L; Hidalgo M; Morrow M; Smith L; Garner A; Sorensen JM; Von Hoff DD; Eckhardt SG
J Clin Oncol; 2000 Jan; 18(1):178-86. PubMed ID: 10623708
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Jones SF; Siu LL; Bendell JC; Cleary JM; Razak AR; Infante JR; Pandya SS; Bedard PL; Pierce KJ; Houk B; Roberts WG; Shreeve SM; Shapiro GI
Invest New Drugs; 2015 Oct; 33(5):1100-7. PubMed ID: 26334219
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
[TBL] [Abstract][Full Text] [Related]
32. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
[TBL] [Abstract][Full Text] [Related]
33. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Gore L; Rothenberg ML; O'Bryant CL; Schultz MK; Sandler AB; Coffin D; McCoy C; Schott A; Scholz C; Eckhardt SG
Clin Cancer Res; 2008 Jul; 14(14):4517-25. PubMed ID: 18579665
[TBL] [Abstract][Full Text] [Related]
34. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
35. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
36. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
37. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ
Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer.
Stratton SP; Saboda KL; Myrdal PB; Gupta A; McKenzie NE; Brooks C; Salasche SJ; Warneke JA; Ranger-Moore J; Bozzo PD; Blanchard J; Einspahr JG; Dorr RT; Levine N; Alberts DS
Nutr Cancer; 2008; 60(3):325-30. PubMed ID: 18444166
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
Garaventa A; Luksch R; Lo Piccolo MS; Cavadini E; Montaldo PG; Pizzitola MR; Boni L; Ponzoni M; Decensi A; De Bernardi B; Bellani FF; Formelli F
Clin Cancer Res; 2003 Jun; 9(6):2032-9. PubMed ID: 12796365
[TBL] [Abstract][Full Text] [Related]
40. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer.
Stratton SP; Alberts DS; Einspahr JG; Sagerman PM; Warneke JA; Curiel-Lewandrowski C; Myrdal PB; Karlage KL; Nickoloff BJ; Brooks C; Saboda K; Yozwiak ML; Krutzsch MF; Hu C; Lluria-Prevatt M; Dong Z; Bowden GT; Bartels PH
Cancer Prev Res (Phila); 2010 Feb; 3(2):160-9. PubMed ID: 20103724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
